Rhaeos

Executive Summary

Rhaeos is a medical device company addressing the critical challenge of detecting shunt malfunctions in hydrocephalus patients. Its flagship product, FlowSense, is a non-invasive, wireless, wearable sensor that assesses cerebrospinal fluid flow through shunts in minutes, replacing the current reliance on costly imaging and subjective symptom evaluation. With over one million Americans living with hydrocephalus and high emergency department discharge rates (70%) and 30-day readmission rates (16%), FlowSense has the potential to significantly reduce unnecessary hospital visits and improve patient outcomes by providing rapid, objective shunt flow assessment at the point of care. The device's non-invasive nature and ease of use position it as a transformative tool for both pediatric and adult hydrocephalus management, addressing a substantial unmet need in neurosurgery and neurology. Despite being in a relatively early stage (founded in 2018, no disclosed funding or revenue), Rhaeos has a compelling value proposition that aligns with healthcare cost-reduction trends. The company's near-term priority is to obtain FDA clearance for FlowSense, which would enable market entry in the US. Subsequent catalysts include initiating a pivotal clinical study to validate diagnostic accuracy and exploring strategic partnerships with shunt manufacturers or hospital systems to accelerate adoption. Given the clear clinical need and the device's innovative approach, Rhaeos is well-positioned for growth, though execution risks remain until regulatory milestones are achieved.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for FlowSense70% success
• Q4 2026Publication of Pivotal Clinical Study Results60% success
• Q1 2027Strategic Partnership with a Major Shunt Manufacturer40% success